Compare ARKO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ARKO | CTNM |
|---|---|---|
| Founded | 1970 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.3M | 550.7M |
| IPO Year | 2021 | 2024 |
| Metric | ARKO | CTNM |
|---|---|---|
| Price | $4.74 | $17.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.2M | 534.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 15.38 | 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,142,799,000.00 | N/A |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.26 | N/A |
| 52 Week Low | $3.71 | $8.60 |
| 52 Week High | $8.76 | $17.51 |
| Indicator | ARKO | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 62.30 |
| Support Level | $4.20 | $13.65 |
| Resistance Level | $5.26 | N/A |
| Average True Range (ATR) | 0.19 | 0.86 |
| MACD | 0.11 | 0.07 |
| Stochastic Oscillator | 65.19 | 96.43 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.